Plaque-Derived FFRCT – the only FFRCT with Plaque Concordance – Planned for FDA Submission in Q4-25

Next-Generation FFRCT + Plaque Analysis

Deliver personalized patient care with the only histologically-validated, objective and quantitative CTA-based FFRCT and plaque analysis.

Accurately measure the direct cause of ischemia while better predicting a patient’s risk of heart attack and stroke.

Clinical Problem

Misdiagnosed Myocardial Ischemia, Heart Attack & Stroke Risk Leads to Poor Outcomes

Myocardial ischemia occurs when blood flow to your heart is reduced, preventing the heart muscle from receiving enough oxygen. This is often the result of plaque buildup inside the artery wall.

Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated.1 Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops.

Elucid is harnessing scientific imaging and artificial intelligence to enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes.

A man and woman hiking
Solution

PlaqueIQ™ Technology

Accurate Clinical Insights Based on Biology

Introducing the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples, to objectively identify both flow limitations and plaque characteristics that may result in a heart attack or stroke.

View Animation

FFRCT now available!

Predictive A.I. backed by 40+ years of clinical research

12 clinical studies and 70+ publications

Powerful. Precise. Proven.

View Publications

Unprecedented accuracy authorized for use in all arteries.

Icon of human heart87%

Accurate prediction of major adverse cardiac events2*

Icon of human heart40%

Better Stroke Prediction3*

*Compared to current stenosis-based guidelines

Elucid Comprehensive
Healthcare Solutions

  • Assess FFRCT and plaque composition with histology-validated software
  • Quantify heart attack and stroke risk with greater accuracy
  • Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital
  • Gain insight into the cause of flow limitations
  • Understand your risk of heart attack and stroke
  • Receive safe and accurate non-invasive diagnostic testing
  • Experience personalized treatment plans
  • Identify promising drug candidates with greater speed and accuracy
  • Reduce clinical trial size, costs and timelines by stratifying high-risk patients
  • Determine a drug candidate’s mechanism of action to enhance safety and dosing

If you are interested in submitting a proposal for a research study, click here.

PlaqueIQ™ Technology

Translate CTA into Scientific Images in 2 Steps

Accurately restore vessel structure and plaque morphology, including lipid rich necrotic core:

1
High-Fidelity Patented
Image Processing
Plaque IQ Technology
2
Complete FFRCT and 3D Plaque Visibility and Analysis

The only CTA-based plaque assessment rigorously validated with histopathology*

Based on expert analysis of microscopic tissue samples by world-renowned cardiovascular pathologists.

*Available in Elucid Research Edition only.

In partnership with:
CV Path Institute
LSU Health New Orleans

The Elucid algorithms demonstrate excellent correlation and are highly accurate for tissue characterization when compared to ex vivo histopathology.”

Renu Virmani, MD

President & Medical Director at CVPath Institute

Secure, Workflow-Oriented A.I.

Icon of Patient in Hospital
1
Works with all CTA scanners using standard acquisition protocols.
Icon of Laptop
2
Accessed via secure, locally deployed software or cloud-based analysis designed to protect sensitive patient data transmission to and from hospital IT systems.

Icon Check

SOC 2
Type II

Icon Check

HIPAA
Type I

Icon of iPad and Doctor
3
Integrates seamlessly into EMR, PACS, and imaging workflow for accurate and timely clinical decision-making.
News

Elucid to Showcase PlaqueIQ at SCCT 2025

Jul 10, 2025 |

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON – July 10, 2025 – Elucid, an AI medical technology company focused on providing physicians with a...

read more
More News
About

See Beyond the Lumen

Our mission is to provide comprehensive and accurate clinical insights, based on ground-truth histology and machine learning, enabling unprecedented precision healthcare for vascular disease. Contact us today to learn more about Elucid clinical solutions:

Our Portfolio

PlaqueIQ

FDA-cleared and CE-marked, non-invasive CTA analysis software providing unprecedented specificity of plaque stability and vessel structure, based on histology.

Next-generation FFRCTand Plaque Analysis

Combination of plaque analysis, based on histology, and FFR for a more direct measure of stress induced ischemia while characterizing plaque risk. Now FDA cleared!

Clinical Research

CTA analysis software with innovative additional features for clinical research and studies.

If you are interested in submitting a proposal for a research study, click here.

Elucid is used to evaluate patient outcomes, safety and clinical efficacy in clinical trials with industry partners, including:

 

Amarin
Karolinkska
Medical University Southern California
National Institutes of Health
Otsuka
Takeda
University of Maryland Medical System
Contact

Contact us today to learn more about Elucid or to schedule a product demo.

Name
By providing a telephone number and submitting this form you are consenting to be contacted by SMS text message. Message & data rates may apply. You can reply STOP to opt-out of further messaging.

Sign up for our CMO newsletter

info@elucidbio.com

2 Park Plaza, Suite 700
Boston, MA 02116

*Compared to current stenosis-based guidelines 1. Stone, Gregg. PROSPECT II/PROSPECT ABSORB. TCT CONNECT 2020 Late Breaking Trial Session. 2. van Assen, M., et al., Automated plaque analysis for the prognostication of major adverse cardiac events. European Society of Radiology, 2019. 3. Lal B.K., et al. Novel Application of Artificial Intelligence Algorithms to Develop a Predictive Model for Major Adverse Neurologic Events in Patients With Carotid Atherosclerosis. Journal of Vascular Surgery. July 2020. DOI: 10.1016/j.jvs.2020.04.306. Compared to current stenosis based guidelines. 4. Elucid Technology FDA 510k summary – K183012; December 21, 2018.